Stocks › PTCT
PTC THERAPEUTICS, INC.
PTCT·Nasdaq·
United States·USD
United States·USD$63.70
+0.05 (+0.08%)
Close · Oct 6, 2026 · Close Prices from Tiingo.com
PTCT
PTC THERAPEUTICS, INC. · Nasdaq
Nasdaq 100S&P 500
Filings
Default90D1Y5YALL
PTCTS&P 500 (rebased)
Congress BuyCongress SellInsider BuyInsider SellForm 1448-K ResultsLobbying
Loading price history…
Daily closes, adjusted for splits and dividends · Close Prices from Tiingo.comHover a marker, every one is a filing · move across the line for the crosshair
Congressional Trades
Recent trades of PTCT by members of U.S. Congress · 0 on record
No congressional trades in PTCT on record.
Whale Activity
Position changes in PTCT reported for 2026-06-30 by 12 tracked institutional filers
- Increased5
- New1
- Held0
- Decreased2
- Closed1
- No prior filing3
| Filer | Shares | Value | Change |
|---|---|---|---|
| BlackRock, Inc. | 14.0M | $1.14B | increased |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 4.9M | $402.0M | increased |
| VANGUARD CAPITAL MANAGEMENT LLC | 3.7M | $305.0M | increased |
| WESTFIELD CAPITAL MANAGEMENT CO LP | 2.0M | $159.6M | — |
| D. E. Shaw & Co., Inc. | 1.5M | $126.3M | decreased |
| Jefferies Financial Group Inc. | 1.4M | $110.7M | — |
| Palo Alto Investors LP | 918.8K | $75.0M | — |
| CITADEL ADVISORS LLC | 747.8K | $61.0M | increased |
| RENAISSANCE TECHNOLOGIES LLC | 723.5K | $59.0M | increased |
| MILLENNIUM MANAGEMENT LLC | 46.5K | $3.8M | new |
| TWO SIGMA INVESTMENTS, LP | 10.7K | $869K | decreased |
| BlackRock, Inc. | 0 | $0 | closed |
KeyVex tracks a curated set of large 13F filers plus the largest positions in recent filings, so this is a sample of institutional activity, not the whole market.
Insider Trading
Net shares bought (+) or sold (−) on the open market by PTCT insiders, by quarter · Form 4
Recent Insider Transactions
1,401 transactions on record · newest first
| Insider | Type | Shares | Price | Value | Date | |
|---|---|---|---|---|---|---|
| STEELE GLENN JR MD PHDDirector · Director | Sale | −12.0K | $65.16 | $782K | Sep 30, 2026 | Form 4 ↗ |
| SCHMERTZLER MICHAELDirector · Director | Sale | −9,624 | $67.83 | $653K | Sep 17, 2026 | Form 4 ↗ |
| SCHMERTZLER MICHAELDirector · Director | Sale | −376 | $68.45 | $26K | Sep 17, 2026 | Form 4 ↗ |
| SCHMERTZLER MICHAELDirector · Director | Sale | −7,006 | $67.35 | $472K | Sep 16, 2026 | Form 4 ↗ |
| SCHMERTZLER MICHAELDirector · Director | Sale | −2,994 | $66.58 | $199K | Sep 16, 2026 | Form 4 ↗ |
| SCHMERTZLER MICHAELDirector · Director | Sale | −10.0K | $67.34 | $673K | Sep 10, 2026 | Form 4 ↗ |
| SCHMERTZLER MICHAELDirector · Director | Sale | −9,428 | $67.79 | $639K | Sep 9, 2026 | Form 4 ↗ |
| SCHMERTZLER MICHAELDirector · Director | Sale | −572 | $68.67 | $39K | Sep 9, 2026 | Form 4 ↗ |
| SCHMERTZLER MICHAELDirector · Director | Sale | −610 | $72.22 | $44K | Aug 27, 2026 | Form 4 ↗ |
| SCHMERTZLER MICHAELDirector · Director | Sale | −11.9K | $71.55 | $851K | Aug 27, 2026 | Form 4 ↗ |
| SCHMERTZLER MICHAELDirector · Director | Sale | −6,874 | $72.74 | $500K | Aug 26, 2026 | Form 4 ↗ |
| SCHMERTZLER MICHAELDirector · Director | Sale | −5,626 | $73.18 | $412K | Aug 26, 2026 | Form 4 ↗ |
| SCHMERTZLER MICHAELDirector · Director | Sale | −9,419 | $70.78 | $667K | Aug 20, 2026 | Form 4 ↗ |
| SCHMERTZLER MICHAELDirector · Director | Sale | −691 | $72.92 | $50K | Aug 20, 2026 | Form 4 ↗ |
| SCHMERTZLER MICHAELDirector · Director | Sale | −2,390 | $71.88 | $172K | Aug 20, 2026 | Form 4 ↗ |
| SCHMERTZLER MICHAELDirector · Director | Sale | −7,165 | $73.67 | $528K | Aug 19, 2026 | Form 4 ↗ |
| SCHMERTZLER MICHAELDirector · Director | Sale | −5,335 | $72.86 | $389K | Aug 19, 2026 | Form 4 ↗ |
| Boulding Mark ElliottEXEC. VP AND CLO | Sale | −969 | $72.90 | $71K | Aug 17, 2026 | Form 4 ↗ |
| Boulding Mark ElliottEXEC. VP AND CLO | Sale | −1,844 | $72.39 | $133K | Aug 17, 2026 | Form 4 ↗ |
| Klein Matthew B.CHIEF EXECUTIVE OFFICER · Director | Sale | −10.3K | $68.57 | $706K | Aug 4, 2026 | Form 4 ↗ |
Fund Holders
Mutual funds and ETFs holding PTCT · SEC Form N-PORT
| Fund | Shares | Value | % of fund | As of |
|---|---|---|---|---|
| iShares Core S&P Small-Cap ETF iShares Trust | 5.0M | $407.6M | 0.37% | Jun 30, 2026 |
| VANGUARD TOTAL STOCK MARKET INDEX FUND VANGUARD INDEX FUNDS | 2.6M | $215.0M | 0.01% | Jun 30, 2026 |
| iShares Russell 2000 ETF iShares Trust | 2.1M | $173.6M | 0.21% | Jun 30, 2026 |
| VANGUARD HEALTH CARE FUND VANGUARD SPECIALIZED FUNDS | 2.3M | $157.1M | 0.41% | Jul 31, 2026 |
| VANGUARD SMALL-CAP INDEX FUND VANGUARD INDEX FUNDS | 1.9M | $155.2M | 0.08% | Jun 30, 2026 |
| State Street(R) SPDR(R) S&P(R) Biotech ETF SPDR SERIES TRUST | 1.4M | $110.7M | 1.03% | Jun 30, 2026 |
| VANGUARD SMALL-CAP GROWTH INDEX FUND VANGUARD INDEX FUNDS | 1.1M | $89.5M | 0.19% | Jun 30, 2026 |
| Janus Henderson Global Life Sciences Fund Janus Investment Fund | 995.6K | $81.2M | 1.40% | Jun 30, 2026 |
| VANGUARD EXTENDED MARKET INDEX FUND VANGUARD INDEX FUNDS | 951.4K | $77.6M | 0.08% | Jun 30, 2026 |
| Hood River Small-Cap Growth Fund Manager Directed Portfolios | 832.3K | $67.9M | 1.02% | Jun 30, 2026 |
Mutual funds and ETFs whose N-PORT filings list PTCT's shares (CUSIP 69366J200), each fund at its latest report since Mar 7, 2026, largest positions first. Bonds, options and short positions are left out.
Corporate Lobbying
Estimated quarterly lobbying spending reported under the LDA, filings naming ptc therapeutics as client
- BGR GOVERNMENT AFFAIRSPTC THERAPEUTICS · 2026 Q2 · HCR$50K
Filing ↗ - PTC THERAPEUTICS, INC.PTC THERAPEUTICS, INC. · 2026 Q2 · HCR, MED, MMM, TAX$170K
Filing ↗ - LMH STRATEGIC SOLUTIONSPTC THERAPEUTICS, INC. · 2026 Q2 · HCR$50K
Filing ↗ - BGR GOVERNMENT AFFAIRSPTC THERAPEUTICS · 2026 Q1 · HCR$50K
Filing ↗ - PTC THERAPEUTICS, INC.PTC THERAPEUTICS, INC. · 2026 Q1 · HCR, MED, MMM, TAX$390K
Filing ↗
Government Contracts
Federal awards to PTC THERAPEUTICS, INC. · USAspending
No federal contract awards found for PTC THERAPEUTICS, INC..
U.S. Patents
Recent USPTO applications naming PTC THERAPEUTICS, INC.
No USPTO patent applications found for PTC THERAPEUTICS, INC..
Annual Financials
From PTCT's 10-K filings · XBRL
No annual XBRL figures on record for PTCT. KeyVex's fundamentals cover about 130 large companies so far.
Stock Splits
Every split and reverse split in the price history
No stock splits in PTCT's price history.
Material Events (8-K)
Corporate events filed with the SEC
- 8-K · Items 7.01, 8.01, 9.01Reg FD disclosure · Other eventsSep 21, 2026
EDGAR ↗ - 8-K · Items 1.01Material agreementAug 28, 2026
EDGAR ↗ - 8-K · Items 7.01, 8.01, 9.01Reg FD disclosure · Other eventsAug 13, 2026
EDGAR ↗ - 8-K · Items 2.02, 5.02, 7.01, 9.01Results of operations · Officer / director change · Reg FD disclosureJul 30, 2026
EDGAR ↗ - 8-K · Items 1.01, 2.03, 3.02, 8.01, 9.01Material agreement · Direct financial obligation · Unregistered sale of equityJun 18, 2026
EDGAR ↗ - 8-K · Items 8.01, 9.01Other eventsJun 16, 2026
EDGAR ↗ - 8-K · Items 5.02, 9.01Officer / director changeJun 9, 2026
EDGAR ↗ - 8-K · Items 5.07Shareholder voteJun 5, 2026
EDGAR ↗ - 8-K · Items 2.02, 7.01, 9.01Results of operations · Reg FD disclosureMay 7, 2026
EDGAR ↗
About PTC THERAPEUTICS, INC.
From SEC EDGAR company records
Industry (SIC 2834)Pharmaceutical Preparations
SectorHealthcare
HeadquartersWARREN, NJ
IncorporatedDE
SEC CIK0001070081 ↗
Former namesPTC THERAPEUTICS INC